Hospital Regional Universitario Málaga, Málaga, Spain; Departamento Oftalmología, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
Unidad de gestión clínica (UGI) Oncología Médica Hospital Regional y Universitario de Málaga, Instituto de Investigación de Biotecnología de Málaga (IBIMA), Málaga, Spain.
Surv Ophthalmol. 2021 Nov-Dec;66(6):951-959. doi: 10.1016/j.survophthal.2021.01.001. Epub 2021 Jan 10.
The incidence and impact of ocular side effects in patients treated with checkpoint inhibitors are not clearly defined. We reviewed prospective phase III clinical trials of checkpoint inhibitors applied in lung cancer, renal cell cancer, and melanoma. Case reports of the occurrence of ocular toxicities in patients receiving immune checkpoint inhibitors were also included. Of the 35 articles corresponding to phase III clinical trials with checkpoint inhibitors, ocular toxicity was described in four. Forty-six clinical cases of ocular toxicity after therapy with checkpoint inhibitors have been reported. The most frequently described ocular toxicities are uveitis, inflammatory orbital disease, and alterations of the ocular surface. Ocular toxicity is underestimated in checkpoint inhibitors clinical trials. Early ophthalmic examination and treatment with corticosteroids may improve the visual prognosis in these patients.
在接受检查点抑制剂治疗的患者中，眼部副作用的发生率和影响尚不清楚。我们回顾了应用于肺癌、肾细胞癌和黑色素瘤的检查点抑制剂的前瞻性 III 期临床试验。还包括接受免疫检查点抑制剂治疗的患者发生眼部毒性的病例报告。在 35 篇与检查点抑制剂相关的 III 期临床试验的文章中，有 4 篇描述了眼部毒性。报道了 46 例接受检查点抑制剂治疗后出现眼部毒性的临床病例。描述最频繁的眼部毒性是葡萄膜炎、炎症性眶病和眼表改变。在检查点抑制剂临床试验中，眼部毒性被低估了。早期眼科检查和皮质类固醇治疗可能改善这些患者的视力预后。
